Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10558941 | 0.79 | ALDH1A1 (0.44) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL6199596 | 0.79 | SMN1; SMN2 (0.41) | MAPK13GCGRMAPK12MAPK11MAPK14 | |
| SCHEMBL9696096 | 0.76 | BTK (0.40) | MTORADKNISCHNR1H2NR1H3 | |
| SCHEMBL528246 | 0.76 | MEN1 (0.46) | MTORADKNISCHNR1H2NR1H3 | |
| SCHEMBL7143721 | 0.75 | DGAT1 (0.51) | NR1H2NR1H3DGAT1MAPK13GCGR | |
| SCHEMBL7139439 | 0.75 | DGAT1 (0.51) | NR1H2NR1H3DGAT1MAPK13GCGR | |
| SCHEMBL9271844 | 0.74 | MTOR (0.42) | MTORADKNISCHNR1H2NR1H3 | |
| SCHEMBL49612 | 0.74 | GAA (0.52) | MTORADKNISCHNR1H2NR1H3 | |
| SCHEMBL57159 | 0.74 | NR1H2 (0.45) | MTORADKNISCHNR1H2NR1H3 | |
| SCHEMBL2094094 | 0.74 | MTOR (0.42) | MTORADKNISCHNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107835814-A | Azabenzimidazoles and their use as ampa receptor modulators | 詹森药业有限公司 | 2018-03-23 | — | — | CN | claimed |
| CN-105111202-A | Synthesis method for 6-bromo-2-phenylimidazo[1,2-alpha]pyridine | SHANDONG YOUBANG BIOCHEMICAL TECHNOLOGY CO LTD | 2015-12-02 | — | — | CN | claimed |
| CN-102548991-B | Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors | HOFFMANN LA ROCHE | 2015-03-25 | — | — | CN | claimed |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | UNIVERSITE DE MONTREAL (CA) | 2025-11-25 | — | — | US | disclosed |
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | UNIVERSITE DE MONTREAL (CA) | 2025-08-28 | — | — | US | disclosed |
| EP-4584259-A1 | CK1ALPHA AND DUAL CK1ALPHA / GSPT1 DEGRADING COMPOUNDS | Innovo Therapeutics, Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12139488-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | Université de Montréal (CA) | 2024-11-12 | — | — | US | disclosed |
| EP-3792256-B1 | PYRIDINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORP (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240317747-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-09-26 | — | — | US | disclosed |
| US-12060353-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | Université de Montréal (CA) | 2024-08-13 | — | — | US | disclosed |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | Université de Montréal (CA) | 2024-07-04 | — | — | US | disclosed |
| US-6579874-B2 | P38 MAP kinase inhibitors; treating Tumor necrosis factor (TNF-alpha) and Interleukin-1 mediated diseases, such as rheumatoid arthritis; imidazole and oxazole derivatives | NOVARTIS AG (CH) | 2003-06-17 | — | — | US | disclosed |
| CN-1378544-A | Substituted azoles compounds | NOVARTIS AG (CH) | 2002-11-06 | — | — | CN | disclosed |
| EP-1224180-A2 | SUBSTITUTED AZOLES | Novartis AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| US-20020049220-A1 | Substituted azoles | NOVARTIS AG (CH) | 2002-04-25 | — | — | US | disclosed |
| WO-2001070703-A2 | SUBSTITUTED 1-(4-AMINOPHENYL)IMIDAZOLES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| CN-1301981-A | Silver halide colour photographic sensitive material | FUJI PHOTO FILM CO LTD (JP) | 2001-07-04 | — | — | CN | disclosed |
| WO-2000063204-A2 | SUBSTITUTED AZOLES | NOVARTIS AG (CH) | 2000-10-26 | — | — | WO | disclosed |
| CN-1147251-A | Tetrasubstd. imidazole derivs., method for preparing same, resulting intermediates, use thereof as drug, and pharmaceutical composition contg. same | ROUSSEL UCLAF (FR) | 1997-04-09 | — | — | CN | disclosed |
| CN-1146765-A | Use of imidazole derivatives for treating disorders involving angiotensin receptors AT 1 and AT2, certain such products preparation thereof, use thereof as drugs, and pharmaceutical composition contai | ROUSSEL UCLAF (FR) | 1997-04-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270207-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | MTOR 1460/4885ADK 1267/4885NISCH 1550/4885 |
| US-20240317747-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, KRAS | MTOR 1460/4885ADK 1267/4885NISCH 1550/4885 |
| US-12139488-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, KRAS | MTOR 1460/4885ADK 1267/4885NISCH 1550/4885 |
| US-12060353-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, KRAS | MTOR 1460/4885ADK 1267/4885NISCH 1550/4885 |
| US-12479842-B2 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | BRAF, NRAS, DPYD | MTOR 1493/4885ADK 1252/4885NISCH 1506/4885 |
| US-20020049220-A1 | Substituted azoles | MAPK1, MAPK4, MAP3K1 | MTOR 614/4885ADK 1336/4885NISCH 4491/4885 |
| US-20240217971-A1 | PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS USES THEREOF FOR TREATING A PROLIFERATIVE DISEASE | BRAF, NRAS, DPYD | MTOR 1493/4885ADK 1252/4885NISCH 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.